TransMedics Group (TMDX) to Release Earnings on Monday

TransMedics Group (NASDAQ:TMDX) is scheduled to release its earnings data after the market closes on Monday, October 28th. Analysts expect TransMedics Group to post earnings of $0.28 per share for the quarter. TransMedics Group has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The firm’s quarterly revenue was up 117.7% on a year-over-year basis. On average, analysts expect TransMedics Group to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

TransMedics Group Stock Performance

TransMedics Group stock opened at $126.60 on Monday. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of 3,165.00 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm’s fifty day moving average price is $152.70 and its 200 day moving average price is $138.75.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,205 shares of company stock valued at $9,981,907 in the last ninety days. Company insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several research analyst reports. Stephens boosted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Morgan Stanley lifted their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a report on Monday, October 7th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of “Buy” and an average price target of $174.30.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.